Investigating a positively-selected chromosome 7 haplotype associated with decreased susceptibility of plasmodium falciparum to artemisinin and lumefantrine in africa
Active Grant Awarded
- Award ID
- R21AI202558
- Recipient
-
Brown University UEI E3FDXZ6TBHW3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $251,562
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 9% complete
- Place of performance
- Providence, RI 02903, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services' National Institutes of Health, through the National Institute of Allergy and Infectious Diseases, awarded Brown University $251,562 on September 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) in grant R21AI202558. The award is classified as a grant, with an ultimate completion date of August 31, 2028, and place of performance in Providence, Rhode Island 02903.
The funded project investigates a positively selected chromosome 7 haplotype linked to decreased susceptibility of Plasmodium falciparum to artemisinin and lumefantrine in Africa. The haplotype centers on the PX1 gene, which the project identified through the recipient's research in Uganda. Aim 1 applies advanced DNA sequencing to thousands of malaria samples from across Africa to map how widely the PX1 PIN haplotype has spread and whether it is evolving alongside other resistance genes. Aim 2 uses laboratory studies, including CRISPR-Cas9 gene editing, to establish whether changes in the PX1 gene directly cause drug resistance and to define how that resistance operates.
Description
- Abstract
- Malaria remains a deadly global health threat, especially in africa, where the most effective treatments-ARTEMISININ combination therapies (ACTS)-appear to be starting to fail. These therapies combine a fast-acting drug (ARTEMISININ-DERIVATIVE) with a longer-acting partner drug. Artemether-lumefantrine is the most widespread act, used in 85% of african malaria cases. Unfortunately, malaria parasites in africa are developing resistance to ARTEMISININ, and there are now signs that lumefantrine is failing. Our research in uganda has pinpointed a specific, fast-spreading segment of the genome (a haplotype) on chromosome 7 of the malaria parasite (plasmodium falciparum) centered on a gene called PX1 that is strongly linked to this decreased susceptibility of the parasite to ARTEMISININ and lumefantrine. In this project, we will first map the spread of this new resistance marker (PX1 pin haplotype) across sub-saharan africa using thousands of samples to determine how widespread the threat is beyond uganda where we think IT originated. Second, we will use lab-based studies, including gene-editing techniques like crispr-CAS9, to definitively prove that the changes in the PX1 gene are the direct cause of the drug resistance and to precisely define how this resistance works. This work is crucial for understanding the extent of this emerging drug resistance threat and for developing urgent new strategies to keep ACTS working and save lives. This research project has two main goals to address the threat of emerging drug resistance in malaria: aim 1: track the spread of resistance: we will use advanced DNA sequencing on thousands of malaria samples from across africa to determine how widely this new drug resistance marker (PX1 pin haplotype) has spread and if IT is evolving alongside other resistance genes. Aim 2: confirm the cause of resistance: we will perform controlled laboratory tests using existing and gene-edited parasites to definitively prove that the changes in the PX1 gene are the cause of the decreased drug sensitivity, specifically to ARTEMISININ and lumefantrine. We will also determine the exact life stage(S) of the parasite that is most resistant together this will give US initial insight into the causative mutations and help inform US of the extent and degree of the danger posed by the PX1 pin marker
Quick answers
Who received award R21AI202558?
R21AI202558 was awarded to Brown University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 18, 2026.
How much is award R21AI202558 worth?
$251,562 has been obligated on R21AI202558.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award